329 related articles for article (PubMed ID: 21277427)
1. What is publication? The case of eltrombopag.
Benham L; Guo L; Turner R
Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
3. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
[No Abstract] [Full Text] [Related]
4. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
[No Abstract] [Full Text] [Related]
5. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.
Piccin A; Amaddii G; Natolino F; Billio A; Cortelazzo S
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s149-50. PubMed ID: 23736912
[No Abstract] [Full Text] [Related]
6. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
[No Abstract] [Full Text] [Related]
7. New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
Francesco R
Eur J Haematol Suppl; 2009 Mar; (71):1-2. PubMed ID: 19200300
[No Abstract] [Full Text] [Related]
8. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Atkinson K
Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
[TBL] [Abstract][Full Text] [Related]
9. [Management of refractory ITP with thrombopoietin receptor agonists].
Tomiyama Y
Rinsho Ketsueki; 2011 Aug; 52(8):627-32. PubMed ID: 21897068
[No Abstract] [Full Text] [Related]
10. Update on romiplostim and eltrombopag indirect comparison.
Cooper K; Matcham J; Helme K; Akehurst R
Int J Technol Assess Health Care; 2014 Jan; 30(1):129-30. PubMed ID: 24485057
[No Abstract] [Full Text] [Related]
11. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
12. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
13. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
14. Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia.
Álvarez Román MT; Fernández Bello I; Arias-Salgado EG; de Paz R; Jiménez Yuste V; Martín Salces M; Butta NV
Br J Clin Pharmacol; 2014 Sep; 78(3):674-6. PubMed ID: 24602175
[No Abstract] [Full Text] [Related]
15. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
Mori M; Kato M; Koh K; Hanada R
Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
[TBL] [Abstract][Full Text] [Related]
16. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
Vibor M; Rogulj IM; Ostojic SK
Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children.
Nolla M; Aladjidi N; Leblanc T; Fernandes H; Ducassou S; Fahd M; Barlogis V; Michel M; Blouin P; Jeziorski E; Benadiba J; Pondarre C; Leverger G; Pasquet M
Blood; 2021 Jan; 137(1):138-141. PubMed ID: 33410895
[No Abstract] [Full Text] [Related]
18. Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim.
Sartori R; Candiotto L; Ruggeri M; Tagariello G
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s151-2. PubMed ID: 24120607
[No Abstract] [Full Text] [Related]
19. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin receptor agonists as second-line therapy in splenectomy-eligible persistent immune thrombocytopenia: a case series.
Vianello F; D'Amore F; Lombardi AM; Caputo I; Friziero A; Da Dalt G
Blood Coagul Fibrinolysis; 2019 Sep; 30(6):295-299. PubMed ID: 31259778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]